Review

Oxygen-regulated transcription factors and their role in pulmonary disease
Gregg L Semenza
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Received: 27 September 2000
Revisions requested: 10 October 2000
Revisions received: 16 October 2000
Accepted: 19 October 2000
Published: 9 November 2000

Respir Res 2000, 1:159–162
© Current Science Ltd (Print ISSN 1465-9921; Online ISSN 1465-993X)

Abstract

The transcription factors nuclear factor interleukin-6 (NF-IL6), early growth response-1 (EGR-1) and hypoxia-inducible factor-1 (HIF-1) have important roles in the molecular pathophysiology of hypoxia-associated pulmonary disease. NF-IL6 controls the production of interleukin (IL)-6 in vascular endothelial cells, which may have anti-inflammatory activity by counteracting effects of IL-1 and IL-8. EGR-1 controls the production of tissue factor by macrophages, which triggers fibrin deposition in the pulmonary vasculature. HIF-1 activates the expression of the vasoconstrictor endothelin-1 in vascular endothelial cells. Angiotensin II induces HIF-1 expression and hypertrophy of pulmonary arterial smooth muscle cells. HIF-1 might therefore have multiple roles in the pathogenesis of pulmonary vascular remodeling.

Keywords: EGR-1, HIF-1, NF-IL6, vascular remodeling

Introduction

Chronic lung disease is a major cause of morbidity and mortality in western populations. It is the fourth leading cause of death in the USA, accounting for 5% of all deaths annually. Although many patients with chronic obstructive lung disease die from infections, the development of alveolar hypoxia is a complication that is also associated with increased mortality. Recent studies have begun to delineate the molecular responses to hypoxia within the lung and its vasculature. An understanding of the molecular pathophysiology of hypoxia-associated pulmonary disease might lead to strategies for the prevention and/or treatment of life-threatening complications. The pathophysiology of chronic diseases must ultimately be understood in terms of changes in gene expression that are mediated by transcription factors. The transcription of several dozen target genes is known to be induced in hypoxic cells (Table 1). Similarly, the activities of several transcription factors are induced in mammalian cells subjected to hypoxia, including activator protein-1 (AP-1), early growth response-1 (EGR-1), hypoxia-inducible factor-1 (HIF-1), high-mobility group (HMG) I(Y), nuclear factor interleukin-6 (NF-IL6), and NF-xB, although the mechanisms by which hypoxia is sensed and the signal is transduced remain enigmatic [1]. This review focuses on the transcription factors EGR-1, HIF-1, and NF-IL6, which are important in the pathophysiology of hypoxic lung disease.

AP-1 = activator protein-1; ECs = endothelial cells; EGR-1 = early growth response-1; ET-1 = endothelin-1; HIF-1 = hypoxia-inducible factor-1; HMG = high-mobility group; IL = interleukin; NF-IL6 = nuclear factor interleukin-6; PAS = Per/ARNT/Sim; SMC = smooth muscle cell; VEGF = vascular endothelial growth factor.
NF-IL6

NF-IL6 (also known as C/EBPβ, for CCAAT-enhancer-binding protein-β) is a basic-leucine-zipper transcription factor that activates IL-6 gene transcription in hypoxic pulmonary vascular endothelial cells (ECs) [2]. The NF-IL6-binding site from the IL-6 promoter was sufficient to direct the expression of a lacZ gene in the heart, kidney, and lung, but not the liver, of transgenic mice subjected to hypoxia or ischemia [3]. The basis for the tissue-specific induction of NF-IL6 expression in vascular ECs is not known. Because IL-6 is a cytokine with anti-inflammatory properties, it might counteract the effects of proinflammatory cytokines. For example, the expression of IL-1 and IL-8 are also induced in hypoxic ECs [4,5] and promote the expression of adherence molecules that recruit activated leukocytes to the vessel wall, leading to vascular leakage and/or thrombus formation [6•]. Thus, NF-IL6 might protect the integrity of the pulmonary vasculature under conditions of hypoxia or ischemia.

EGR-1

EGR-1 (also known as ZIF268) is a zinc-finger transcription factor that is expressed in hypoxic mononuclear phagocytes [7]. EGR-1-mediated production of tissue factor by monocytes leads to hypoxia-induced fibrin deposition in the pulmonary vasculature [8]. In the lungs of mice subjected to hypoxia, EGR-1 and tissue factor are co-induced in bronchial and vascular smooth muscle and alveolar macrophages [9]. When wild-type mice are exposed to an ambient O₂ concentration of 6% (reduced from the 21% O₂ in room air), EGR-1 and tissue factor expression are induced in the lung and marked vascular deposition of fibrin is observed, whereas none of these responses occur in knockout mice lacking expression of the gene encoding protein kinase C-β [10••]. The mechanism by which hypoxia activates protein kinase C-β activity in mononuclear phagocytes is unknown but this activity seems to be crucial for the induction of EGR-1 activity and tissue factor production. EGR-1 also mediates tissue factor production by endothelial cells in response to stimulation by vascular endothelial growth factor (VEGF) [11], the hypoxia-induced expression of which is mediated by HIF-1 (see below), indicating that hypoxia induces tissue factor expression by two different mechanisms that both involve EGR-1. Thus, in contrast to NF-IL6, hypoxia-induced EGR-1 activity promotes pulmonary vascular thrombosis.

HIF-1

Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric basic helix–loop–helix–Per/ARNT/Sim (PAS)-domain transcription factor composed of HIF-1α and HIF-1β subunits [12]. In contrast to NF-IL6 and EGR-1, HIF-1 is expressed in most, if not all, nucleated mammalian cells in response to hypoxia; several dozen target genes have been identified, including VEGF (Table 1). HIF-1α is expressed constitutively, whereas HIF-1α expression in the lung is

| Hypoxia-inducible gene expression | Transcription factor |
|----------------------------------|----------------------|
| Adenylate kinase 3               | HIF-1                |
| α1-adrenergic receptor           | HIF-1                |
| Adrenomedullin                   | HIF-1                |
| Aldolase A                       | HIF-1                |
| Aldolase C                       | HIF-1                |
| Carbonic anhydrase-9             | HIF-1                |
| Ceruloplasmin                    | HIF-1                |
| Cyclooxygenase-2                 | HMG I(Y), NF-κB       |
| Endothelin-1                     | HIF-1                |
| Enolase-1                        | HIF-1                |
| Erythropoietin                   | HIF-1                |
| GADD153                          | Not determined       |
| Glucose transporter-1            | HIF-1                |
| Glucose transporter-2            | HIF-1                |
| Glyceraldehyde-3-phosphate dehydrogenase | HIF-1          |
| Heme oxygenase-1                 | AP-1, HIF-1          |
| Hexokinase-1                     | HIF-1                |
| Hexokinase-2                     | HIF-1                |
| Insulin-like growth factor-2 (IGF-2) | HIF-1              |
| IGF-binding protein-1            | HIF-1                |
| IGF-binding protein-2            | HIF-1                |
| IGF-binding protein-3            | HIF-1                |
| Interleukin-6                    | HIF-1                |
| Lactate dehydrogenase A          | HIF-1                |
| Nitric oxide synthase-2          | HIF-1                |
| NIP3                             | HIF-1                |
| Ornithine decarboxylase          | Not determined       |
| p21                              | HIF-1                |
| p27                              | Not determined       |
| p35srj                           | HIF-1                |
| Phosphofructokinase L            | HIF-1                |
| Phosphoglycerate kinase-1        | HIF-1                |
| Plasminogen activator inhibitor-1| HIF-1                |
| Prolyl-4-hydroxylase α(I)         | HIF-1                |
| Pyruvate kinase M                | HIF-1                |
| Tissue factor                    | EGR-1                |
| Transferrin                      | HIF-1                |
| Transferrin receptor             | HIF-1                |
| Transforming growth factor β3    | HIF-1                |
| Triosephosphate isomerase        | HIF-1                |
| Tyrosine hydroxylase             | AP-1                 |
| Vascular endothelial growth factor (VEGF) | HIF-1            |
| VEGF receptor FLT-1              | HIF-1                |

*See [12] for literature citations.
regulated by the inspired \( O_2 \) concentration [13] (Fig. 1). Homozygous-null knockout mice that completely lack HIF-1\( \alpha \) expression die at mid-gestation owing to the failure of embryonic vascularization [14–16]. Mice heterozygous for the null allele (\( \text{Hif1a}^{+/–} \)), and thus partly deficient for HIF-1\( \alpha \) expression, develop normally and are indistinguishable from their wild-type littermates under normoxic conditions. Wild-type mice exposed to 10% \( O_2 \) develop pulmonary hypertension in response to chronic hypoxia. Medial wall thickening in pulmonary arterioles results in increased pulmonary arterial pressure and right ventricular hypertrophy. The remodeling is progressive and if continued leads to cor pulmonale. In \( \text{Hif1a}^{+/-} \) mice, the hypoxia-induced muscularization of pulmonary arterioles is significantly impaired, resulting in significantly less medial wall thickening, pulmonary artery hypertension, and right ventricular hypertrophy after 3 weeks at 10% \( O_2 \) [17••].

Although the pathophysiology of pulmonary hypertension is complex [18], a major component of this process is the elaboration of peptides, such as endothelin-1 (ET-1) and angiotensin II, that induce smooth muscle cell (SMC) contraction and hypertrophy. ET-1 expression is induced within the pulmonary vasculature of hypoxic rats [19], and ET\( \text{A} \)-receptor antagonists prevent/reverse chronic hypoxia-induced pulmonary hypertension [20]. A HIF-1-binding site in the \( \text{ET-1} \) gene promoter is required for hypoxia-induced transcription [21•], suggesting that ET-1 mRNA expression by hypoxic pulmonary vascular ECs is mediated by HIF-1.

Expression of angiotensin-converting enzyme (ACE), which converts angiotensin I to angiotensin II, is also induced within the pulmonary vasculature of hypoxic rats [22]. The administration of captopril, an ACE inhibitor, or losartan, a type 1 angiotensin receptor antagonist, also attenuates the development of hypoxic pulmonary hypertension [23]. Angiotensin II, which induces vascular SMC hypertrophy, has recently been shown to induce HIF-1\( \alpha \) expression [24••]. These results suggest that HIF-1 might be required for the angiotensin-induced hypertrophy of vascular SMCs in the hypoxic lung.

In addition to SMC hypertrophy, hypoxia is associated with increased pulmonary vascular tone, which also reduces luminal diameter. One determinant of vascular tone is the production by ECs of ET-1, a potent SMC vasoconstrictor. The activity of voltage-gated potassium (\( K_v \)) channels is another important determinant of SMC membrane potential and pulmonary vasomotor tone. Acute hypoxia inhibits \( K_v \) channel activity, resulting in the depolarization and vasoconstriction of pulmonary artery SMCs. Chronic hypoxia is associated with downregulation of \( K_v1.2 \) and \( K_v1.5 \) mRNA expression [25], but the involvement of HIF-1 or another hypoxia-induced transcription factor in this process has not yet been demonstrated.

**Conclusion**

NF-IL6, EGR-1, and HIF-1 mediate important physiological responses to chronic hypoxia in macrophages and pulmonary vascular ECs and SMCs. NF-IL6 might mediate adaptive anti-inflammatory responses, but definitive studies with knockout mice have not been performed. In contrast, analysis of \( \text{Egr1}^{–/–} \) and \( \text{Hif1a}^{+/-} \) mice has provided definitive evidence that EGR-1 and HIF-1 mediate pathophysiologic responses to chronic hypoxia, suggesting that pharmacologic inhibition of these factors might be
useful in the prevention or treatment of hypoxia-induced pulmonary vascular pathology.

Acknowledgements

Work in the author’s laboratory is supported by grants from the National Institutes of Health (R01-DK39869 and R01-HL5338).

References

Articles of particular interest have been highlighted as:

• of special interest
•• of outstanding interest

1. Semenza GL: Perspectives on oxygen sensing. Cell 1999, 99: 281–284.

2. Yan SF, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, Brett J, May L, Stern D: Induction of interleukin 6 (IL-6) by hypoxia in vascular cells: central role of the binding site for nuclear factor-IL6. J Biol Chem 1995, 270:11463–11471.

3. Yan SF, Zou YS, Mendelsohn M, Gao Y, Naka Y, Du Yan S, Pinsky D, Stern D: Nuclear factor interleukin 6 motifs mediate tissue-specific gene transcription in hypoxia. J Biol Chem 1997, 272: 4287–4294.

4. Karakurum M, Shreeniwas R, Chen J, Pinsky D, Yang SD, Anderson M, Sunouchi K, Major J, Hamilton T, Kowabara K, et al: Hypoxic induction of interleukin-8 gene expression in human endothelial cells. J Clin Invest 1994, 93:1564–1570.

5. Shreeniwas R, Koga S, Karakurum M, Pinsky D, Kaeiser E, Brett J, Woltzky BA, Norton C, Plochinski J, Benjamin W, et al: Hypoxia-mediated induction of endothelial cell interleukin-1α: an autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 1992, 90:2333–2339.

6. Michiela C, Arnould T, Remacle J: Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions. Biochim Biophys Acta 2000, 1497:1–10.

An excellent review of EC-leukocyte interactions involved in vascular inflammatory responses to hypoxia.

7. Yan SF, Zou YS, Gao Y, Zhai C, Mackman N, Lee SL, Milbrandt J, Pinsky D, Kiesel W, Stern D: Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci USA 1998, 95:8298–8303.

8. Lawson CA, Yan SD, Yan SF, Liao H, Zhou YS, Sobel J, Kiesel W, Stern DM, Pinsky DJ: Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest 1999, 99:1729–1738.

9. Yan SF, Lu J, Xu L, Zou YS, Tongers J, Kiesel W, Mackman N, Pinsky DJ, Stern DM: Pulmonary expression of early growth response-1, a biphasic time course and effect of oxygen concentration. J Appl Physiol 2000, 88:2303–2309.

10. Yan SF, Lu J, Zou YS, Kiesel W, Mackman N, Leitges M, Steinberg S, Pinsky D, Stern D: Protein kinase C-β and oxygen deprivation: a novel Egr-1-dependent pathway for fibrin deposition in hypoxic vasculature. J Biol Chem 2000, 275:11921–11928.

Using knockout mice, the authors demonstrate that fibrin deposition secondary to tissue factor production in the lungs of hypoxic mice requires PKC-β-dependent induction of EGR-1 activity.

11. Mechtcheriakova D, Wlachos A, Holzmueller H, Binder BR, Hofer E: Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999, 93:3811–3823.

12. Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000, 88:1474–1480.

13. Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenman K, Semenza GL: Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor 1 in the lung. Am J Physiol 1998, 275:L819–L826.

14. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL: Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 1998, 12:149–162.

15. Kotch LE, Iyer NV, Laughner E, Semenza GL: Defective vascularization of HIF-1α-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 1999, 209: 254–267.

16. Ryan HE, Lo J, Johnson RS: HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 1999, 18: 3005–3015.

17. Yu AY, Shimoda LA, Iyer NV, Hulo DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, Semenza GL: Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α. J Clin Invest 1999, 103:691–696.

18. In comparison with wild-type littermates, the muscularization of pulmonary arteries is significantly decreased in heterozygous HIF-1α-null mice exposed to hypoxia for 3 weeks, indicating that partial HIF-1α deficiency is sufficient to impair hypoxia-induced pulmonary vascular remodeling.

19. Stenman KR, Mecham RP: Cellular and molecular mechanisms of pulmonary vascular remodeling. Am J Physiol 1997, 59: 89–144.

20. Li H, Chen SJ, Chen YF, Meng QC, Durand J, Oparil S, Elton TS: Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol 1994, 77:1451–1459.

21. DiCarlo VS, Chen SJ, Meng QC, Durand J, Yano M, Chen YF, Oparil S: ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rats. Am J Physiol 1995, 269:L690–L697.

22. Hu J, Discher DJ, Bishopic NH, Webster KA: Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun 1998, 245:894–899.

The authors demonstrate the presence of a HIF-1-binding site, 5′-ACGGTCG-3′, located 118–125 bp 5′ to the transcription start site, that is required for hypoxia-induced ET-1 gene expression in cardiac myocytes.

23. Morrell NW, Atochina EN, Morris KG, Danilov SG, Stenman KR: Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest 1995, 96:1823–1833.

24. Morrell NW, Morris KG, Stenman KR: Role of angiotensin-convert- ing enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 1996, 269:H1188–H1194.

25. Richard DE, Berra E, Pouyssegur J: Hypoxia regulates the induction of hypoxia-inducible factor 1α (HIF-1α) in vascular smooth muscle cells. J Biol Chem 2000, 275:28783–28791.

The authors demonstrate that the exposure of aortic SMCs to angiotensin II, platelet-derived growth factor-BB, or thrombin results in a marked induction of HIF-1α expression under non-hypoxic conditions. Angiotensin II-induced HIF-1α expression is blocked by treatment with diphenylene iodonium or catalase, suggesting the involvement of NAPDH oxidase-derived hydrogen peroxide in the signal transduction pathway.

26. Wang J, Juhaszova M, Rubin LJ, Yuan X-J: Hypoxia inhibits gene expression of voltage-gated K+ channel α subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997, 100:2347–2353.

Author’s affiliation: Institute of Genetic Medicine and Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Correspondence: Gregg L Semenza M.D PhD, Johns Hopkins Hospital, CMSC-1004, 600 North Wolfe Street, Baltimore, MD 21287-3914, USA. Fax: +1 410 955 0494; e-mail: gsemenza@jhmi.edu